Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Lasser

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
The American Journal of Psychiatry|March 3, 2005
Remission in schizophrenia: proposed criteria and rationale for consensusNancy C Andreasen, William T Carpenter, John M Kane, et al.
The Journal of Clinical Psychiatry|February 9, 2012
Lifespan persistence of ADHD: the life transition model and its applicationAtilla Turgay, David W Goodman, Philip Asherson, et al.
The Journal of Clinical Psychiatry|August 16, 2013
Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled studyLenard A Adler, Bryan Dirks, Patrick F Deas, et al.
American Heart Journal|October 1, 1983
Left ventricular hemangioma masquerading as Mycoplasma pericarditisW E Boden, E J Funk, R A Carleton, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 13, 2013
Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phasesRobert A Lasser, Bryan Dirks, Henry Nasrallah, et al.
Journal of Attention Disorders|February 15, 2013
ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 YearsFrank A López, Ann Childress, Ben Adeyi, et al.
The Journal of Clinical Psychiatry|September 13, 2006
A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorderGeorge M Simpson, Ramy A Mahmoud, Robert A Lasser, et al.
Annals of General Psychiatry|January 31, 2007
Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing intervalGeorges M Gharabawi, Natalie C Gearhart, Robert A Lasser, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 9, 2006
Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuationMark Hyman Rapaport, Georges M Gharabawi, Carla M Canuso, et al.
Alzheimer'S Research & Therapy|December 10, 2017
A phase III randomized trial of gantenerumab in prodromal Alzheimer's diseaseSusanne Ostrowitzki, Robert A Lasser, Ernest Dorflinger, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
The American Journal of Psychiatry|March 3, 2005
Remission in schizophrenia: proposed criteria and rationale for consensusNancy C Andreasen, William T Carpenter, John M Kane, et al.
The Journal of Clinical Psychiatry|February 9, 2012
Lifespan persistence of ADHD: the life transition model and its applicationAtilla Turgay, David W Goodman, Philip Asherson, et al.
The Journal of Clinical Psychiatry|August 16, 2013
Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled studyLenard A Adler, Bryan Dirks, Patrick F Deas, et al.
American Heart Journal|October 1, 1983
Left ventricular hemangioma masquerading as Mycoplasma pericarditisW E Boden, E J Funk, R A Carleton, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 13, 2013
Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phasesRobert A Lasser, Bryan Dirks, Henry Nasrallah, et al.
Journal of Attention Disorders|February 15, 2013
ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 YearsFrank A López, Ann Childress, Ben Adeyi, et al.
The Journal of Clinical Psychiatry|September 13, 2006
A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorderGeorge M Simpson, Ramy A Mahmoud, Robert A Lasser, et al.
Annals of General Psychiatry|January 31, 2007
Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing intervalGeorges M Gharabawi, Natalie C Gearhart, Robert A Lasser, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 9, 2006
Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuationMark Hyman Rapaport, Georges M Gharabawi, Carla M Canuso, et al.
Alzheimer'S Research & Therapy|December 10, 2017
A phase III randomized trial of gantenerumab in prodromal Alzheimer's diseaseSusanne Ostrowitzki, Robert A Lasser, Ernest Dorflinger, et al.
Pageof 7